PRTK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRTK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-05), Paratek Pharmaceuticals's current share price is $2.23. Paratek Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was $1.48. Paratek Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 1.51.
The historical rank and industry rank for Paratek Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Paratek Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 7.33. The lowest was 0.56. And the median was 1.57.
PRTK's Cyclically Adjusted PS Ratio is not rankedThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Paratek Pharmaceuticals's adjusted revenue per share data for the three months ended in Jun. 2023 was $0.664. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.48 for the trailing ten years ended in Jun. 2023.
The historical data trend for Paratek Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paratek Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 1.01 | 2.37 | 1.30 | 1.82 | 1.35 |
For the Biotechnology subindustry, Paratek Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Paratek Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Paratek Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 2.23 | / | 1.48 | |
= | 1.51 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paratek Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 is calculated as:
For example, Paratek Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Jun. 2023 (Change) | * | Current CPI (Jun. 2023) |
= | 0.664 | / | 128.7287 | * | 128.7287 | |
= | 0.664 |
Current CPI (Jun. 2023) = 128.7287.
Paratek Pharmaceuticals Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201309 | 0.299 | 98.790 | 0.390 |
201312 | 0.201 | 98.326 | 0.263 |
201403 | 0.266 | 99.695 | 0.343 |
201406 | 0.229 | 100.560 | 0.293 |
201409 | 0.114 | 100.428 | 0.146 |
201412 | 0.234 | 99.070 | 0.304 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.001 | 101.863 | 0.001 |
201703 | 0.001 | 102.862 | 0.001 |
201706 | 0.275 | 103.349 | 0.343 |
201709 | 0.000 | 104.136 | 0.000 |
201712 | 0.181 | 104.011 | 0.224 |
201803 | 0.000 | 105.290 | 0.000 |
201806 | 0.001 | 106.317 | 0.001 |
201809 | 0.002 | 106.507 | 0.002 |
201812 | 0.529 | 105.998 | 0.642 |
201903 | 0.049 | 107.251 | 0.059 |
201906 | 0.063 | 108.070 | 0.075 |
201909 | 0.121 | 108.329 | 0.144 |
201912 | 0.265 | 108.420 | 0.315 |
202003 | 0.190 | 108.902 | 0.225 |
202006 | 0.204 | 108.767 | 0.241 |
202009 | 0.259 | 109.815 | 0.304 |
202012 | 0.325 | 109.897 | 0.381 |
202103 | 0.317 | 111.754 | 0.365 |
202106 | 1.132 | 114.631 | 1.271 |
202109 | 0.436 | 115.734 | 0.485 |
202112 | 0.579 | 117.630 | 0.634 |
202203 | 0.436 | 121.301 | 0.463 |
202206 | 0.520 | 125.017 | 0.535 |
202209 | 0.505 | 125.227 | 0.519 |
202212 | 1.303 | 125.222 | 1.339 |
202303 | 0.513 | 127.348 | 0.519 |
202306 | 0.664 | 128.729 | 0.664 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Minnie Baylor-henry | director | C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803 |
Kristine Peterson | director | AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355 |
Timothy R Franson | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Jeffrey Stein | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Thomas John Dietz | director | C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804 |
Evan Loh | director, officer: CEO | 75 KNEELAND STREET, BOSTON MA 02111 |
William M. Haskel | officer: CLO, General Counsel & Sec. | ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073 |
Adam Woodrow | officer: President & Chief Commercial | C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111 |
Randall B. Brenner | officer: Chief Development & Regulatory | C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116 |
Robert S Radie | director | 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355 |
Rolf K Hoffmann | director | LORBEERWEG 7, WEGGIS V8 CH-6353 |
Michael Bigham | director, officer: Exec. Chairman of the Board | 890 WINTER STREET, WALTHAM MA 02451 |
James D Dondero | 10 percent owner | 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201 |
Douglas W. Pagan | officer: Chief Financial Officer | 75 KNEELAND STREET, BOSTON MA 02111 |
Omega Fund Iv, L.p. | 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
From GuruFocus
By Marketwired • 10-05-2023
By Marketwired • 09-21-2023
By PRNewswire • 07-12-2023
By Marketwired • 08-25-2023
By Marketwired • 06-27-2023
By Marketwired • 07-17-2023
By Marketwired • 09-07-2023
By Marketwired • 07-18-2023
By Marketwired • 08-03-2023